Doherty Catherine T. sold $5.5M of DGX

Doherty Catherine T. (Executive Vice President) sold 22,105 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $248.02 ($245.45–$251.24, $5.48M total) across 7 trades on 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doherty Catherine T.
Published Nov 6, 2026, 12:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Bearish
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership stake, which may be interpreted by investors as a bearish signal, though the pre‑arranged nature tempers the impact.

02

Market read

The filing provides fresh, material information about insider holdings, offering a modest trading cue for DGX.

03

What to watch

Potential upcoming earnings or strategic moves not disclosed may be the real driver of the sale.

Relevance 5/10Novelty 5/10Timing: after-hours filing on 2026‑11‑05

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates the sale was pre‑scheduled, reducing speculation about motive.

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

Executive Vice President Catherine Doherty sold 22,105 shares for $5.48M via a 10b5‑1 plan, reducing her stake to 71,949 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $5.5M sale by a top executive is material for a mid‑cap stock and can influence short‑term sentiment, though the transaction was pre‑arranged.

Market effects

Minimal impact on the broader healthcare diagnostics sector; insider sales are company‑specific.

Limited to U.S. markets where DGX trades.

Low global relevance.

Counterpoint

The sale could be purely procedural under a 10b5‑1 plan, not reflecting negative outlook.

Key entities

  • Quest Diagnostics Inc.

    U.S. provider of diagnostic testing services, ticker DGX.

  • Catherine T. Doherty

    Executive Vice President of Quest Diagnostics, reporting the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.